

**This is the final draft of the contribution published as:**

**Leuthold, D., Klüver, N., Altenburger, R., Busch, W. (2019):**

Can environmentally relevant neuroactive chemicals specifically be detected with the locomotor response test in zebrafish embryos?

*Environ. Sci. Technol.* **53** (1), 482 – 493

**The publisher's version is available at:**

<http://dx.doi.org/10.1021/acs.est.8b04327>

1 **Journal:**

2 ES&T

3 **Title:**

4 Can environmentally relevant neuroactive chemicals specifically be detected with the  
5 locomotor response test in zebrafish embryos?

6 **Authors:**

7 David Leuthold<sup>1\*</sup>, Nils Klüver<sup>2</sup>, Rolf Altenburger<sup>1</sup>, Wibke Busch<sup>1</sup>

8 <sup>1</sup>Helmholtz-Centre for Environmental Research – UFZ, Dept. Bioanalytical Ecotoxicology,  
9 Permoserstr. 15, 04318 Leipzig, Germany


10 <sup>2</sup>Helmholtz-Centre for Environmental Research – UFZ, Dept. Cell Toxicology, Permoserstr.  
11 15, 04318 Leipzig, Germany

12 \*corresponding author: david.leuthold@ufz.de

13 **Abstract**

14 Chemicals considered as neuroactive (such as certain pesticides, pharmaceuticals and  
15 industrial chemicals) are among the largest groups of bioactive substances recently detected  
16 in European rivers. However, the determination of nervous system-specific effects has been  
17 limited using *in vitro* tests or conventional endpoints including lethality. Thus,  
18 neurobehavioral tests using *in vivo* models (e.g. zebrafish embryo) have been proposed as  
19 complementary approaches. To investigate the specificity and sensitivity of a light-dark  
20 transition locomotor response (LMR) test in 4 to 5 days post fertilization zebrafish with  
21 respect to different modes of action (MoAs), we analyzed a set of 18 environmentally  
22 relevant compounds with various anticipated MoAs. We found that exposure-induced  
23 behavioral alterations were reproducible and dependent on concentration and time.  
24 Comparative and quantitative analyses of the obtained locomotor patterns revealed that  
25 behavioral effects were not restricted to compounds primarily known to target the nervous  
26 system. A clear distinction of MoAs based on locomotor patterns was not possible for most  
27 compounds. Furthermore, chemicals with an anticipated same MoA did not necessarily  
28 provoke similar behavioral phenotypes. Finally, we determined an increased sensitivity ( $\geq 10$ -  
29 fold) compared to observed mortality in the LMR assay for 5 of 8 neuroactive chemicals as  
30 opposed to non-neuroactive compounds.

31 **Graphical Abstract**



32

## 33 1. Introduction

34 Aquatic ecosystems face the contamination with multiple anthropogenic chemicals including  
35 pesticides, pharmaceuticals and industrial chemicals. An analysis of chemical monitoring  
36 data from major European river catchments revealed that besides compounds with unknown  
37 modes of action (MoAs), especially neuroactive chemicals are representing the largest group  
38 of detectable compounds with known MoA <sup>1</sup>. Although *in silico* target prediction approaches  
39 for neurotoxicity are a desirable long term goal, their development requires large amounts of  
40 bioactivity data <sup>2</sup>. However, due to the limited availability of *in vitro* assays able to capture  
41 effects relevant for the nervous system <sup>3</sup>, the detection of neuroactive chemicals and the  
42 assessment of their acute and sublethal toxicity is challenging <sup>4</sup>. Using *in vivo* assays such  
43 as the acute fish embryo toxicity (FET) test with zebrafish (*Danio rerio*) <sup>5</sup> as a potential  
44 alternative for the acute fish test with adults <sup>6</sup>, it has been shown that certain neuroactive  
45 compounds provoke lower acute toxicity in early life stages of fish compared to adult stages  
46 <sup>7-9</sup>. Behavior-based assays such as the light-dark transition locomotor response (LMR) test  
47 have therefore been described of being specifically sensitive for neuroactive compounds and  
48 to increase sensitivity beyond acute toxicity levels <sup>9</sup>. Beyond that, the diagnostic capacity of  
49 behavioral tests in embryonic and larval zebrafish has been demonstrated in neuroactive  
50 drug discovery <sup>10, 11</sup>. Conversely, whether behavioral profiling has the potential to support the  
51 assessment of complex chemical mixtures such as environmental samples, e.g. through  
52 identification of mixture toxicity drivers, needs to be elucidated. However, behavior assays,  
53 such as the LMR test, lack a uniform test design <sup>12</sup> and it is known that minor methodological  
54 changes (e.g. age, incubation conditions, light driving, plate format) can alter its outcome <sup>13</sup>.  
55 Consequently, comparisons between results from different studies are difficult.

56 To apply behavioral tests for the diagnosis and assessment of neuroactive chemicals,  
57 specificity and sensitivity measures need to be determined. Therefore, we performed  
58 behavior-based toxicity tests on a set of 18 chemicals representing various MoAs to  
59 investigate whether the obtained LMR patterns are sufficiently specific to potentially indicate  
60 the anticipated MoAs. Furthermore, we hypothesized that neuroactive chemicals should

61 provoke neurobehavioral effects at concentration ranges well below acute toxicity levels as  
62 opposed to non-neuroactive chemicals. Considering concentration and time dependency of  
63 toxicity during zebrafish development and investigating lethal and behavioral effects we could  
64 not clearly show a general specificity of the applied LMR assay for the investigated  
65 neuroactive compounds but found an increased sensitivity for certain chemicals of this group.

## 66 **2. Materials and methods**

### 67 **2.1. Fish cultivation, embryo collection, chemicals and stock preparation**

68 Details on fish cultivation, embryo collection, chemicals and stock preparation are given in  
69 Supporting Information (S1).

### 70 **2.2. Experimental design and determination of exposure concentrations**

71 Exposure was initiated at 96 hours post fertilization (hpf) (up to 120 hpf) in order to avoid  
72 exposure-induced developmental abnormalities potentially affecting embryonic movement.  
73 Because no mortality data were available for this time window, concentrations initially  
74 selected for testing were based on toxicity data obtained in earlier studies using exposure  
75 windows of 24-96 hpf and 0-96 hpf, respectively. These tests were conducted according to  
76 OECD test guideline no. 236 <sup>5</sup> adapted to 7.5-mL glass vials using 3 individuals per 6 mL test  
77 solution in triplicate (26 °C, 75 rpm, Edmund Bühler SM-30 Control, 14:10 h light:dark).  
78 Subsequently, for behavioral experiments, a dilution series was calculated for each  
79 compound considering mortality, bioconcentration and maximum water solubility, yielding 7  
80 to 17 test concentrations per compound (Supporting Table S1).

### 81 **2.3. Exposure and light-dark transition locomotor response test**

82 Sixteen 96 hpf zebrafish embryos (ZFEs) per treatment were exposed to a linear  
83 concentration series of a single chemical. Subsequently, individuals were transferred  
84 separately to single wells of 96-well polystyrene plates which were covered with cell culture  
85 test plate lids and sealed with laboratory film. Until the end of the test at 120 hpf, plates were  
86 incubated at 28 °C in the dark. ZFEs were analyzed in a light-dark transition locomotor

87 response (LMR) test after 1.5, 6.0, and 22.5 h of exposure (i.e. at 97.5, 102, and 118.5 hpf),  
88 using a ZebraBox monitoring enclosure with corresponding software in tracking mode  
89 (ViewPoint Life Sciences, Lyon, France). The total measurement time comprised 80 min with  
90 a photoperiod sequence of 10min dark, 10 min light, and a twice repeated dark-light  
91 transition of 20 and 10 min, respectively. The first dark and light phase were used for  
92 acclimation and were not considered for quantitation. Subsequent to each LMR test, mortality  
93 was evaluated based on absence of heartbeat and coagulation of the embryo. Dead  
94 individuals were excluded from behavioral data analysis at the respective time point of  
95 investigation. More details are given in Supporting Information S1.

#### 96 **2.4. Analysis of locomotor activity data**

97 Locomotor activity was recorded in terms of total distance moved and was integrated every  
98 single minute for each treatment (T) and control group (C) ( $n = 16$  embryos each).  
99 Photoperiods repeated twice were treated as replicates. I.e. data were aggregated as  
100 median total distance covered per minute yielding 30 min in total (20 min dark, 10 min light).  
101 Differences between C and T were considered significant in case the confidence intervals  
102 (CIs) of C and T did not overlap (Supporting Information S1).

#### 103 **2.5. Multidimensional scaling (MDS) and cluster analysis**

104 MDS coordinates were calculated (KNIME Distance Matrix Calculate node) using the median  
105 distance moved per minute for each treatment and control group. Heatmap generation and  
106 hierarchical clustering were conducted using the heatmap.2 function from the R package  
107 gplots (version 2.13.0, <sup>14</sup>). The latter was performed on a selected subset of data (Supporting  
108 Information S1).

### 109 **3. Results**

110 In this study, we analyzed a set of 18 environmentally relevant compounds representing  
111 eight MoA groups with at least two model compounds per group in order to investigate their  
112 corresponding behavioral phenotypes and the specificity and sensitivity of the LMR assay.

113 We included anticipated neuroactive compounds (e.g. insecticides, specific pharmaceuticals)  
114 representing four different mechanisms of nervous system interaction as well as substances  
115 without known neuroactive properties (e.g. anti-inflammatory pharmaceuticals, industrial  
116 chemicals) and chemicals with unknown MoAs in fish (e.g. herbicides, fungicides) (Table 1).

117 **Table 1\***. Modes of action and model compounds selected for locomotor response analyses.

	Molecular target	Mode of action	Compound	Substance group	Use	MW (g/mol)	logD (pH7.4)
Neuroactive	Acetylcholinesterase	AChE inhibition <sup>a,b</sup>	Diazinon	Organothiophosphate	Pesticide (insecticide, acaricide, repellent, veterinary substance)	304.35	3.80
	(AChE)	AChE inhibition <sup>c</sup>	Triphenylphosphate	Organophosphate	Flame retardant, plasticizer	326.28	4.12
	Serotonin reuptake	Selective serotonin reuptake (SSR) inhibition <sup>d</sup>	Citalopram hydrobromide	Nitrile	Drug (antidepressant)	405.311	1.27
	(SSR/SNR)	Serotonin-norepinephrine reuptake (SNR) inhibition <sup>d</sup>	D,L-Venlafaxine	Tertiary amino compound	Drug (antidepressant)	277.4	1.43
	Nicotinic acetylcholine receptor	Competitive nACh-R agonism <sup>a,b</sup>	(-)-Nicotine	Pyrimidine	Pesticide (insecticide)	162.23	0.37
	(nACh-R)	Competitive nACh-R agonism <sup>a,b</sup>	Imidacloprid	Neonicotinoid	Pesticide (insecticide, veterinary substance)	255.66	0.29
	Gamma-aminobutyric acid receptor	GABA-gated Cl <sup>-</sup> -channel antagonism <sup>a,b</sup>	Endosulfan	Organochlorine	Pesticide (insecticide, acaricide)	406.93	3.87
(GABA-R)	GABA-gated Cl <sup>-</sup> -channel antagonism <sup>a,b</sup>	Fipronil	Phenylpyrazole	Pesticide (insecticide, veterinary substance)	437.15	3.71	
Non-neuroactive	Cyclooxygenase	COX inhibition, inhibition of leukocyte migration <sup>d</sup>	Diclofenac sodium	Monocarboxylic acid	Drug (nonsteroidal anti-inflammatory agent)	318.13	1.37
	(COX)	COX inhibition <sup>d</sup>	Naproxen sodium	Methoxynaphtalene	Drug (nonsteroidal anti-inflammatory agent)	252.25	0.45
	Photosystem II	PSII inhibition <sup>a</sup>	Isoproturon	Urea	Herbicide	206.28	2.45
	(PSII)	Inhibition of photosynthesis <sup>a</sup>	Diuron	Phenylurea	Herbicide	233.1	2.75
		Methaemoglobin production <sup>e</sup>	3,4-Dichloroaniline	Unclassified	Metabolite	162.02	2.60
	Estrogen receptor	E-R agonism <sup>f</sup>	4-n-Nonylphenol	Alkyl phenol	Surfactant (adjuvant, other substances)	220.35	5.13
	(E-R)	E-R agonism <sup>g</sup>	Bisphenol A	Bisphenol	Plasticizer, pesticide (fungicide)	228.29	3.63
	Protein synthesis	Methionine synthesis (MetS) inhibition <sup>a</sup>	Cyprodinil	Anilinopyrimidine	Pesticide (fungicide)	225.29	3.62
	(MetS)	Methionine synthesis (MetS) inhibition <sup>a</sup>	Pyrimethanil	Anilinopyrimidine	Pesticide (fungicide)	199.25	3.18
Solvent	Multiple	Narcotic, metabolic acidosis, ocular damage <sup>h</sup>	Methanol	Alcohol	Solvent	32.04	-0.52

118 \*MoA information were compiled from (a) Pesticide Properties Database, (b) Insecticide Resistance Action Committee database, (c) <sup>15</sup>, (d)


119 Drugbank, (e) <sup>16</sup>, (f) <sup>17</sup>, (g) <sup>18</sup>, and (h) <sup>19</sup> (relevance of MoA in fish is not necessarily considered here). Molecular weight (MW) according to

120 manufacturer description. logD (pH 7.4) was estimated using the PhysChem Profiler module of ACD/Percepta (ACD/Labs, build 2726. 27 Nov  
121 2014). Chemical structures of the tested compounds are provided in Supporting Figure S1.

122 To prevent developmental toxicity-induced morphological alterations, potentially affecting  
123 embryonic locomotion, we did not initiate exposure before 96 hpf. Behavioral phenotypes  
124 were recorded after 1.5, 6.0, and 22.5 h of exposure in a concentration-dependent manner.  
125 Furthermore, we assumed that the surveillance of behavioral alterations throughout the  
126 complete time window of exposure should allow for the identification of appropriate exposure  
127 durations that exclusively reveal the primary behavioral mechanism of a compound in the  
128 absence of morphological alterations.

### 129 3.1. Concentration and time dependency of behavioral profiles


130 The underlying principle of the light-dark transition test is the rapid alteration from basal to  
131 sharply increasing locomotor activity induced by an immediate switch from visible to invisible  
132 light. Prior to the finally applied experimental setup we conducted tests on the design, time  
133 point and duration of measurement. Within the established setup, we recognized that the  
134 behavioral phenotype of untreated ZFEs was reproducible at each time point but changed  
135 with age, especially between 102 and 118.5 hpf. Within this temporal frame embryos became  
136 more active (Figure 1). Hence, the performed LMR assay proved to be robust and suitable in  
137 order to display potentially distinct behavioral phenotypes in a time dependent manner.



138

139 **Figure 1.** Locomotor activity is developmental stage-specific. Boxplots show the distance  
140 moved per minute of untreated zebrafish embryos ( $n=688$ ) of different age: (A) 97.5, (B)  
141 102.0 and (C) 118.5 hpf, respectively.

142 We found that the age-specific profiles changed after chemical treatment depending on  
143 concentration. Using the example of 3,4-dichloroaniline, we show how swimming behavior  
144 was altered after treatment with three different concentrations for 1.5 and 22.5 h (Figure 2A,  
145 B). The activity profiles changed with exposure time and concentration, e.g. from constant  
146 locomotion (Figure 2A; red line) to complete inhibition of movement (Figure 2B; red line) and  
147 vice versa (Figure 2A, B; yellow line). Normalizing the observed profiles to control levels  
148 using differences in activity between exposed embryos and untreated controls translated into  
149 a heatmap indicating hypo- (blue) and hyperactivity (red), respectively, for overall ten  
150 analyzed concentrations of 3,4-dichloroaniline (Figure 2C, D). We observed that high and low  
151 concentrations caused hypolocomotion compared to control levels whereas median  
152 concentrations caused hyperactivity in ZFEs (Figure 2C, D). Additionally, looking at e.g. a  
153 concentration of 271  $\mu\text{M}$ , 3,4-dichloroaniline caused hyperactivity at 97.5 hpf but hypoactivity  
154 at 118.5 hpf (1.5 and 22.5 h post exposure, respectively; Figure 2C, D). Our observations on  
155 concentration but also time dependent behavioral phenotypes were not restricted to 3,4-  
156 dichloroaniline but rather showed up for all of the investigated compounds (Supporting Figure  
157 S2).



158

159 **Figure 2.** Behavioral profiles of 3,4-dichloroaniline are concentration and time dependent.

160 Grey (control) and colored lines (treatment): median distance moved per minute ( $n=16$

161 individuals per treatment) at (A) 97.5 (1.5 h of exposure) and (B) 118.5 hpf (22.5 h of

162 exposure), respectively. Shaded areas: respective 95% CIs. (C, D) Heatmaps indicate the

163 difference in activity between treatment and control for all tested concentrations.

### 164 3.2. Behavioral phenotype-based clustering of chemicals

165 In order to gain an overview on the relation between behavioral profiles obtained with our

166 assay, we calculated pairwise Euclidean distances between all locomotor patterns of each of

167 the 18 compounds and every concentration at each investigated time point (1.5, 6.0, 22.5 h

168 of exposure between 96 and 118.5 hpf). We, therefore, used MDS considering all recorded

169 behavioral profiles in a joint analysis. Results are presented in three plots separated

170 according to exposure duration. Additionally, warm and cold colors indicate anticipated  
171 neuroactive and other MoAs, respectively (Figure 3).

172 As described above, the movement pattern of controls was subjected to age-specific  
173 changes as it can also be seen from the MDS representations in which the control cluster  
174 moves from the top right corner to the top left side over time (Figure 3; grey shaded areas).





175 We found that behavioral alterations were not restricted to neuroactive compounds but also  
176 comprised the other investigated MoA classes. Depending on the level and duration of  
177 exposure each of the 18 tested compounds altered locomotion.

178 After 1.5 h of exposure (Figure 3A) we observed the most pronounced alterations in  
179 movement (largest spatial distance to controls) at various concentrations of AChE inhibitors  
180 (22-87  $\mu\text{M}$  diazinon and 5-11  $\mu\text{M}$  triphenylphosphate, yellow points and triangles) as well as  
181 for diuron (34-83  $\mu\text{M}$ , light blue triangles), 3,4-dichloroaniline (101-271  $\mu\text{M}$ , turned light blue  
182 triangles) and naproxen (668-1236  $\mu\text{M}$ , dark blue triangles). These data points have a close  
183 spatial proximity, indicating that these compounds shared a similar behavioral phenotype at  
184 the given concentrations. In contrast to the tested AChE inhibitors, isoproturon (83-215  $\mu\text{M}$ ,  
185 light blue points) and diclofenac (1-12  $\mu\text{M}$ , dark blue points) did not show close spatial  
186 relation to their MoA analogues and formed separate, compound-specific clusters (Figure  
187 3A). Additionally, endosulfan (0.1-0.2  $\mu\text{M}$ , pink circles) and nicotine (10.1  $\mu\text{M}$ , 20.2-30.3  $\mu\text{M}$ ,  
188 red circles) provoked patterns distinct from other compounds (Figure 3A). Besides MoA- and  
189 compound-related clusters, we found that despite citalopram, venlafaxine, imidacloprid,  
190 diclofenac, naproxen, isoproturon, and diuron, 11 chemicals converged towards a common  
191 data point (MDS coordinates  $\sim[66, 2]$ ) in at least one concentration (Figure 3A). The  
192 characteristic behavioral profile behind was the complete inhibition of movement throughout  
193 the LMR test which was often indicative for mortality at a later time point of investigation.

194 After 6 h of exposure (Figure 3B), we observed that diazinon (34-58  $\mu\text{M}$ , yellow triangles)  
195 and triphenylphosphate (7-11  $\mu\text{M}$ , yellow points) did not remarkably change their spatial

196 position indicating temporally stable behavior profiles for these concentrations, whereas  
197 lower concentrations of triphenylphosphate (5  $\mu\text{M}$ ) and higher concentrations of diazinon  
198 (87  $\mu\text{M}$ ) converged closer to control levels. This was also observed for naproxen (Figure 3B;  
199 491-908  $\mu\text{M}$ , dark blue triangles). This time dependent shift led to a separation of diuron  
200 (light blue triangles) and 3,4-dichloroaniline (turned light blue triangles) forming a more  
201 independent cluster (Figure 3B). However, data points of AChE and PSII inhibitors are  
202 located close to each other, indicating that the underlying behavioral phenotypes were not  
203 unique and specific for the respective MoAs. In contrast, a unique pattern for endosulfan was  
204 observed (0.05-0.20  $\mu\text{M}$ , pink points), being, however, different from the pattern of its tested  
205 MoA analogue fipronil (pink triangles) (Figure 3B).

206 As mentioned above, at 118.5 hpf (Figure 3C) we observed the most pronounced shift in  
207 locomotor activity by control groups as compared to previous time points of investigation  
208 (also see Figure 1). Furthermore, similarities of the tested SSR/SNR inhibitors citalopram  
209 (22-172  $\mu\text{M}$ , orange points) and venlafaxine (56-225  $\mu\text{M}$ , orange triangles) became more  
210 obvious after 22.5 h of exposure (Figure 3C). They converged in a concentration-dependent  
211 manner towards the MDS region described above as being characteristic for absolute  
212 inactivity (Figure 3C). Additionally, exposure to endosulfan (0.05-0.79  $\mu\text{M}$ , pink points) and  
213 3,4-dichloroaniline (101-165  $\mu\text{M}$ , turned light blue triangles) led to the most pronounced  
214 alterations in behavior (large spatial distance from the control cluster) (Figure 3C). At a  
215 concentration of 61  $\mu\text{M}$ , 3,4-dichloroaniline (turned light blue triangle) formed a cluster with  
216 its MoA analogues diuron (153  $\mu\text{M}$ , light blue triangle) and isoprotruron (215-340  $\mu\text{M}$ , light  
217 blue points) (Figure 3C). However, this cluster could not be identified as MoA-specific since  
218 behavioral profiles of triphenylphosphate (7-11  $\mu\text{M}$ , yellow triangles) and nonylphenol  
219 (12  $\mu\text{M}$ , dark green point) were located in the same area as the PSII inhibitors (Figure 3C).




221 **Figure 3.** Multidimensional scaling plots of behavioral profiles. Same color: same mode of  
222 action group. Each symbol refers to a specific concentration. Rows: exposure duration. Light  
223 grey areas: spatial expansion of control groups in the two-dimensional space. Clusters  
224 discussed in the main text are highlighted. Each of the 3 plots is directly comparable with  
225 each other since multidimensional scaling was based on a common distance matrix  
226 calculated from median moved distances per minute within a measurement period of 30 min  
227 in total (20 min dark, 10 min light).

228 In order to identify phenotypes potentially indicative for a certain MoA we systematically  
229 selected specific patterns (Supporting Information S1) for each compound and performed  
230 hierarchically clustering. The results are shown in a heatmap in Figure 4.

231 Most behavioral profiles changed remarkably over time. For example naproxen (c7=668  $\mu$ M),  
232 led to an overall activation in movement after 1.5 h of exposure (Figure 4A) which turned into  
233 hypoactive behavior with peak hyperlocomotion at the transition from dark to light after 22.5 h  
234 of exposure which was exclusively observed for naproxen (Figure 4B). After 22.5 h of  
235 exposure, two main clusters were observed, whereof the bottom cluster consisted of  
236 behavioral profiles mainly representing hypoactivity throughout the test period (Figure 4B).  
237 These profiles mainly included concentrations which induced lethality (>5%) at this time point  
238 (Figure 4B). We only identified endosulfan (c9=0.8  $\mu$ M) and pyrimethanil (c6=185  $\mu$ M) to  
239 cause both hyperactivity and lethality at 118.5 hpf (Figure 4B). Please note that only vital  
240 embryos were considered for LMR data analyses. Furthermore, we found several combined  
241 profiles where activity was increased in the dark phase, but decreased in the light phase (e.g.  
242 methanol, c9=720 mM) and *vice versa* (e.g. diuron, c6=83  $\mu$ M). Some compound-related  
243 clusters indicating a decrease in activity were found for bisphenol A (c6=38  $\mu$ M-c8=77  $\mu$ M)  
244 (Figure 4A) and fipronil (c5=1  $\mu$ M-c10=9  $\mu$ M) (Figure 4B).

245 Overall, clusters did not show clear differentiation of response patterns of neuroactive  
246 compounds from other MoA classes. Independent of exposure duration, we could not clearly  
247 identify MoA-specific clusters. We merely found that e.g. 3,4-dichloroaniline (c7=165  $\mu$ M,

248 c8=271  $\mu$ M) and diuron (c6=83  $\mu$ M) clustered according to behavioral profiles mainly  
249 characterized by hyperactivity (Figure 4A). However, e.g. the neuroactive diazinon  
250 (c10=58  $\mu$ M) also caused a behavioral phenotype similar to the two PSII inhibitors (Figure  
251 4A, B). Furthermore, diazinon (c11=87  $\mu$ M) grouped with its MoA analogue  
252 triphenylphosphate (c5=5  $\mu$ M) after 1.5 but not after 22.5 h of exposure (Figure 4A, B). Also  
253 the SNR/SSR inhibitors venlafaxine (c6=0.2  $\mu$ M) and citalopram (c9=22  $\mu$ M) exclusively  
254 clustered 1.5 h post exposure (Figure 4A).



255

256 **Figure 4.** Behavioral phenotype-based clustering of chemicals with various modes of action

257 after (A) 1.5 and (B) 22.5 h of exposure for selected concentrations (systematic data

258 selection is described in Supporting Information). Concentrations are listed in Supporting  
259 Table S1. Color key and histogram indicate the difference in median distance moved  
260 between treatment and control and the distance frequency distribution of shown profiles,  
261 respectively.

### 262 **3.3. Sensitivity of LMR in relation to acute toxicity**

263 In order to assess the sensitivity of behavioral responses in relation to mortality, we  
264 conducted concentration response analysis of both endpoints and compared EC50 and LC50  
265 after 1.5, 6.0 and 22.5 h of exposure. Figure 5 additionally shows the contribution of hypo-  
266 and hyperactivity to the total observed effect and how these changed over time. All  
267 concentration-response curves are shown in Supporting Figure S3.

268 Figure 5A shows that exposure to diazinon for 1.5 and 6.0 h induced behavioral alterations  
269 mainly driven by hyperactivity (red pies), whereas 22.5 h exposure led to hypoactivity-  
270 dominated phenotypes (blue pie). Additionally, we determined a reduced effect intensity in  
271 terms of difference in the total distance moved at EC50 (smaller pie chart size) after 22.5 h of  
272 exposure compared to the previous two time points. Furthermore, behavioral and lethal  
273 effects in terms of EC50 (pie chart centers) and LC50 (triangles), converged over time. Along  
274 those lines we found that the sensitivity of behavioral responses in many cases decreased  
275 over time or that at least sensitivity did not remarkably increase with exposure duration. In  
276 contrast, citalopram and the investigated GABA-receptor antagonists endosulfan and fipronil  
277 led to lower EC50 values after prolonged exposure, i.e. 6.0 and/or 22.5 h (Figure 5E, M, O).

278 Similar to diazinon, we observed time dependent changes in behavioral phenotypes for  
279 numerous other compounds characterized by initial hyperactivity followed by hypoactive  
280 behavior after 6.0 and/or 22.5 h of exposure. Also, the intensity of observed behavioral  
281 effects was subjected to temporary changes. For e.g. diclofenac we observed a slight but  
282 significant hyperactivation in movement (EY50=75.5 mm) after 1.5 h of exposure, which  
283 turned into an even weaker response (EY50=10 mm) after 6.0 h and finally completely  
284 disappeared after 22.5 h of exposure (Figure 5B). On the other hand, we found that the two

285 investigated serotonin reuptake inhibitors, the two nACh-R agonists, as well as  
286 triphenylphosphate, fipronil, bisphenol A and methanol remarkably increased effect intensity  
287 over time.

288 We additionally compared behavioral and lethal effect concentrations and found that  
289 exposure to diclofenac led to the most sensitive behavioral response ( $EC_{50}(1.5\text{ h})=0.7\ \mu\text{M}$ )  
290 of all investigated compounds and time points being two orders of magnitude more sensitive  
291 than its corresponding  $LC_{50}(1.5\text{ h})=165\ \mu\text{M}$ . However, we did not observe behavioral  
292 alterations after 22.5 h of exposure but increasing mortality ( $LC_{50}(22.5\text{ h})=77\ \mu\text{M}$ ). Except for  
293 venlafaxine and isoproteron which caused behavioral alterations in the absence of acute  
294 toxicity, we determined that behavioral and lethal effect concentrations increasingly  
295 converged with exposure duration. In this context, we merely found few compounds leading  
296 to an at least 10-fold increase in sensitivity (compared to mortality at the respective time  
297 point) for the respective exposure time window, including citalopram (22.5 h) and endosulfan  
298 (22.5 h). In addition, the ratio of  $LC_{50}(22.5\text{ h})/EC_{50}(1.5\text{ h})$  was  $>10$  for imidacloprid and  
299 diuron (see Supporting Table S2 for effect values).




301 **Figure 5.** Sensitivity of behavioral responses (EC50) and their relation to lethal effect  
302 concentrations (LC50) over time. The center of each pie chart represents the EC50 of the  
303 LMR test. Size of pie chart: EY50 (total effect, i.e. absolute difference in distance moved  
304 between treatment and control at EC50). Blue and red pies indicate contribution of hypo- and  
305 hyperactive behavior to the overall observed effect, respectively. LC50 at the respective time  
306 point (same exposure duration) is indicated by black triangles and the maximum tested  
307 concentration (LMR assay) by dashed vertical lines. Error bars indicate 95% CI ( $n \geq 160$   
308 individuals per compound). LC50 values above the maximum tested concentration were  
309 extrapolated.

310 Since the exposure window applied here (96-118.5 hpf) deviates in duration and  
311 developmental stage from the one applied in the acute FET test according to OECD test  
312 guideline 236 where exposure is performed from 0-96 hpf, we compared our results with  
313 acute FET data obtained in toxicity tests conducted from 0-96 hpf and from 0-120 hpf, the  
314 latter covering the developmental stage we used for exposure in our study. To get an idea of  
315 whether certain compounds and MoAs have a higher toxicity in adult life stage, we also  
316 included acute fish toxicity (AFT) test<sup>6</sup> data previously summarized by Scholz et al.<sup>20</sup>. Figure  
317 6 summarizes the data that we had available for this comparison (Supporting Table S2).

318 The figure indicates that LC50 values obtained after 96 and 120 h of embryo exposure are  
319 nearly identical. No mortality was detected for imidacloprid, endosulfan, fipronil and  
320 venlafaxine in the 96 h FET test. We therefore compared our results to the limit of water  
321 solubility (Sw) as a reference value. Except for diuron and 3,4-dichloraniline, our LC50  
322 values for 22.5-h exposure (between 96 and 118.5 hpf) are in most cases slightly higher due  
323 to shorter exposure but are within a range of one order of magnitude compared to acute  
324 toxicity after 0-96 and 0-120 hpf exposure, respectively. The even weaker acute toxicity of  
325 diuron and 3,4-dichloroaniline indicates a higher susceptibility of the early embryonic  
326 developmental stage to these compounds.

327 Behavior-based EC50 values, determined after 22.5 h of exposure, were in most cases in a  
328 similar range as acute FET data. However, deviations by at least factor 10 from the reference  
329 value (96-h LC50 or Sw) could be observed for citalopram, venlafaxine, endosulfan, fipronil,  
330 nicotine, and 3,4-dichloroaniline. At the same time, we observed an increasing sensitivity in  
331 mortality for three of these five compounds (fipronil, citalopram, nicotine) when exposure was  
332 initiated at 96 hpf. Considering this, a ratio between lethality and locomotor effects larger  
333 than 10 was only found for the SSR/SNR inhibitors citalopram, and venlafaxine, as well as  
334 for the GABA-R antagonist endosulfan, while venlafaxine did not lead to lethality at all. In  
335 comparison with the AFT test our study shows that results obtained with the FET test are in a  
336 similar range for 5 out of 7 available datasets except for the neuroactive substances  
337 endosulfan and nicotine, where the adult fish has a higher sensitivity. For such compounds a  
338 supplementation of the FET test with behavioral responses can increase the sensitivity of the  
339 fish embryo in the context of animal alternative testing.



340

341 **Figure 6.** Comparison of acute fish embryo toxicity (FET, circles), acute fish toxicity (AFT,  
 342 crosses) and locomotor response effects (LMR, triangles) for selected exposure time  
 343 windows. In case no mortality was observed within 96 h, the water solubility limit of the  
 344 respective compound was used as reference point. Broken lines indicate orders of  
 345 magnitude deviations from LC50 (0-96 hpf). Methanol not shown (see Supporting Table S2  
 346 for effect concentrations).

#### 347 **4. Discussion**

348 The occurrence of a variety of chemicals potentially acting as neurotoxicants in the aquatic  
349 environment has been shown <sup>1, 21</sup>. Organisms are expected to be exposed to mixtures of  
350 potentially neuroactive and other compounds. Next to neuroactive pharmaceuticals, which  
351 show a low acute toxicity but high pharmacological efficacy by design (reviewed e.g. by  
352 Khetan and Collins <sup>22</sup>), also insecticides and compounds with unintended neuroactivity are a  
353 matter of concern due to their environmental occurrence. The detection of neurotoxicity is  
354 difficult as availability of acute *in vitro* assays is limited and compounds with a neurotoxic  
355 MoA have previously been demonstrated to show weak toxicity in the acute FET test <sup>9</sup>.  
356 Hence, ecologically relevant endpoints such as behavior have been proposed for improving  
357 the detection of ecotoxicological and potentially adverse effects of neurochemicals <sup>9, 23</sup>.

358 In the present study we applied a light-dark transition test on ZFEs (4-5 days post  
359 fertilization, dpf) with a time and dose-resolved experimental design in order to investigate  
360 the specificity and sensitivity of this assay in comparison to lethality measures. Therefore, we  
361 analyzed substances with an anticipated neuroactive MoA as well as compounds  
362 presumably exerting other MoAs.

363 First, we demonstrated that ZFEs between 4 and 5 dpf display a reproducible locomotor  
364 pattern which is specific to their developmental stage. Our finding is directly in line with a  
365 previous study of de Esch et al. <sup>24</sup> who found that the motor activity pattern of *D. rerio* (5-  
366 7 dpf) is influenced by fish age. Different from 4 dpf old individuals, 5 dpf old ZFEs were  
367 characterized particularly by a sharp light-dark response and a comparatively higher level of  
368 basal locomotor activity under light conditions. Additionally, we found that the variability in  
369 activity between individuals is also stage-dependent and lowest when using the ~5-dpf stage.  
370 Another aspect which suggests the use of stages  $\geq 4$  dpf derives from the fact, that the  
371 inflation of the first posterior chamber of the swim bladder which represents a vital organ  
372 regulating buoyancy takes place around 4.5 dpf <sup>25</sup>.

373 The dependency of motor responses from the duration of exposure has been demonstrated  
374 for e.g. certain dopaminergic drugs <sup>26</sup>. As this assay is not standardized, exposure regimes  
375 vary in literature ranging from early developmental exposures to late embryonic short-term  
376 exposures <sup>12</sup>. Taking into consideration that the nervous system of *D. rerio* is still developing  
377 during embryogenesis (reviewed e.g. by Schmidt et al. <sup>27</sup>), the use of different developmental  
378 stages and exposure scenarios may lead to significant differences in the results of behavior  
379 studies. Variable and complex processes of embryogenesis provide varying targets for  
380 chemicals and interactions may lead to adverse outcomes directly or via a cascade of  
381 effects. Consequently, observed behavioral alterations may have different causes including  
382 developmental (neuro)toxicity and morphological defects.

383 The developmental stage-specific expression of nervous system receptors during  
384 embryogenesis poses a challenge for neurobehavioral research. For example, 23 different  
385 GABA<sub>A</sub> receptor subunits were identified in zebrafish <sup>28</sup>. Monesson-Olson et al. <sup>29</sup>  
386 investigated the expression of eight  $\alpha$  subunit-encoding genes for their spatial and temporal  
387 expression at 1, 2, and 4 dpf and found that two out of eight genes were not expressed  
388 before 1 dpf and one gene even not before 2 dpf. Transcripts for all  $\alpha$  subunit-encoding  
389 genes were only detected at 4 dpf <sup>29</sup>. This finding ties in well with our observations wherein  
390 the anticipated GABA-gated chloride channel antagonists endosulfan and fipronil did not  
391 cause mortality within 0-4 dpf, while mortality emerged during a 4-5 dpf exposure. Hence, the  
392 availability of molecular targets and their physiological functionality is essential in order to  
393 provoke MoA-related effects detectable at organism level. Therefore, it seems more  
394 reasonable to assume that neurobehavioral effects related to the primary MoA in certain  
395 cases may be found rather in advanced life stages due to the further developed functionality  
396 of corresponding receptor systems. Therefore, we applied a 24-h short-term exposure  
397 scenario starting 4 dpf and including multiple time points of measurement. Our results on  
398 behavioral responses to 18 compounds occurring as soon as 1.5 h post chemical treatment  
399 confirm that short-term exposure is a reasonable choice for the detection of anticipated MoA-  
400 specific effects. Furthermore, we observed in case of e.g. AChE inhibitors time-dependent

401 shifts of the behavioral phenotype from hyper- to hypoactivity. Contrary to the absent  
402 expression of GABA<sub>A</sub> receptors during 1 and 2 dpf<sup>29</sup>, AChE is already present during early  
403 embryonic development of *D. rerio*<sup>30, 31</sup>. Primarily, it is involved in the termination of signal  
404 transmission mediated by the neurotransmitter acetylcholine at neuromuscular junctions and  
405 cholinergic brain synapses (reviewed e.g. by Soreq and Seidman<sup>32</sup>). Hence, the partial  
406 inhibition of AChE and subsequent accumulation of acetylcholine can be expected to  
407 produce a hyperactive locomotor phenotype. The results of our experiments on the AChE  
408 inhibitors diazinon and triphenylphosphate found clear support for this hypothesis. However,  
409 we showed that hyperactivity was only found after 1.5 and 6.0 h but not after 22.5 h of  
410 exposure, although we still detected significant inhibition of AChE at that time point  
411 (Supporting Figure S4). Furthermore, besides its primary biological role in acetylcholine-  
412 mediated neurotransmission, AChE has been shown to be involved in the neuronal and  
413 muscular development of the ZFE<sup>33</sup>. Consequently, the duration and the time point of  
414 exposure initiation influences the way of interference and observed behavioral phenotypes.  
415 Particularly, alterations in neuronal development not visible morphologically but at a  
416 behavioral level can distort the recognition of a specific MoA. In this context, Yang et al.<sup>34</sup>  
417 demonstrated that 48-h exposure of zebrafish (24-72 hpf) to chlorpyrifos oxon altered the  
418 touch-evoked swimming responses which were, however, accompanied by significant  
419 inhibition in outgrowth of sensory and motoneurons below exposure levels inducing mortality  
420 or obvious developmental defects. For the SNR inhibitor venlafaxine it was found that  
421 exposure (0-120 hpf) reduced the larval swimming activity in the dark and also promoted  
422 neurogenesis<sup>35</sup>. These two examples indicate that potential secondary side effects not  
423 visible by eye can impact on behavioral phenotypes when applying long-term exposures.  
424 Considering this in connection with our findings, we propose to use short-term exposure  
425 scenarios of older embryonic stages when aiming at capturing molecular initiating events and  
426 their directly related outcomes at organism level. Overall these findings are in accordance  
427 with the experimental design used by e.g. Kokel et al.<sup>11</sup> and Bruni et al.<sup>10</sup> who applied  
428 chemical treatments for 1-10 h for phenotypical differentiation of specifically acting drugs.

429 The specificity of the LMR assay towards distinct MoAs was of interest for this study.  
430 Therefore, we selected and investigated anticipated neuroactive compounds as well as  
431 compounds with other anticipated MoAs. In line with previous studies we found that  
432 neuroactive chemicals including AChE inhibitors, SSR/SNR inhibitors, nACh-R agonists, and  
433 GABA-R antagonists cause behavioral effects detectable with the LMR assay. Moreover, we  
434 demonstrate that behavioral alterations are not restricted to chemicals known to be  
435 neuroactive. Here we show that e.g. herbicides, anti-inflammatory drugs and fungicides can  
436 alter locomotor activity, too. This is consistent with what has been reported in some studies  
437 showing that e.g. photosynthesis inhibitors such as diuron <sup>36</sup> and atrazine <sup>37</sup>, certain COX  
438 inhibitors <sup>38</sup>, or fungicides such as imazalil <sup>39</sup> are able to disturb embryonic swimming  
439 behavior in the absence of acute toxicity and obvious morphological defects. An explanation  
440 provided for the observations made for the fungicide imazalil and the herbicide atrazine was  
441 their ability to inhibit AChE in zebrafish <sup>37, 39</sup>. A similar result was obtained in a study by  
442 Bretaud et al. <sup>40</sup> who found significant inhibition of brain AChE in juvenile goldfish (*Carassius*  
443 *auratus*) after 24 h of exposure to 2.1  $\mu$ M diuron. By contrast, Velki et al. <sup>41</sup> did not detect  
444 AChE inhibition by the herbicide diuron in zebrafish exposed from 2-98 hpf up to a  
445 concentration of 8.6  $\mu$ M. However, they found significant changes in thigmotactic and  
446 locomotor behavior in 120 hpf ZFEs at a concentration of 4.3  $\mu$ M <sup>36</sup>. Apart from the studies  
447 cited here, the availability of literature investigating behavioral effects and underlying  
448 molecular mechanisms of chemicals that are not assumed to be neuroactive is scarce. This  
449 highlights that little is known about the neuroactive potential of most compounds in  
450 organisms like fish. Hence, the limited knowledge about the transferability of MoAs that were  
451 defined in biological models other than *D. rerio* calls for more detailed investigation of  
452 underlying mechanisms. In addition, ZFEs are capable to biotransform xenobiotics already  
453 during early embryogenesis <sup>42</sup>. Hence, observed temporal changes in the behavioral  
454 phenotype may in certain cases rather be attributed to unknown transformation products than  
455 parent compounds.

456 The observed behavioral profiles in our study comprised of both hypo- and hyperactivity in  
457 ZFEs for the majority of investigated compounds. Activity patterns changed with increasing  
458 concentrations meaning that there is not one single behavioral profile being representative  
459 for a certain compound. At high exposure levels, which we assume to induce a general  
460 disturbance of homeostasis shortly before apparent toxicity (similar to cytotoxicity in cell-  
461 based *in vitro* assays) the majority of chemicals caused complete inhibition of locomotion  
462 which indicated lethality. Frequently, we observed multiphasic concentration-response  
463 patterns especially for those compounds which induced hyperactivity at low concentrations  
464 while higher concentrations caused hypoactivation. Such biphasic concentration response  
465 patterns were also reported by Ali et al. <sup>43</sup> who analyzed a set of 60 water-soluble  
466 compounds using a light-dark transition assay in 120 hpf ZFEs exposed from 24 hpf. The  
467 multiphasic behavioral effects of certain compounds may reflect their ability to impact on  
468 different neurotransmitter systems or other molecular targets in a dose dependent manner.  
469 However, based on the lacking specificity of observed behavioral responses, we cannot  
470 distinguish such patterns. Furthermore, some chemicals may have multiple MoAs potentially  
471 affecting behavior in different ways. E.g. chronic exposure to the AChE inhibitor  
472 triphenylphosphate has been shown to alter hormone levels in zebrafish <sup>44</sup>. However,  
473 mechanisms of acute developmental and chronic (neuro)toxicity are not necessarily covered  
474 by our approach.

475 Evidence for MoA-indicative clusters, at least temporarily, could be identified for some  
476 substances including those assigned as AChE and SSR/SNR inhibitors. Especially the  
477 SSR/SNR inhibitors citalopram and venlafaxine were different compared to other compounds  
478 and MoAs at 118.5 hpf (22.5 h of exposure) due to their systematic concentration-dependent  
479 decrease of locomotor activity which could be observed with concentrations from around 1 to  
480 >100  $\mu$ M. For all other compounds behavioral effects ranged within one order of magnitude.  
481 Our findings on venlafaxine are directly in line with recent results of Thompson et al. <sup>35</sup> who  
482 found a significant dose-related reduction in the activity level of zebrafish (120 hpf) in the  
483 dark. We also found phenotypic similarities between the hyperactivity-dominated profiles of

484 the AChE inhibitors diazinon and triphenylphosphate which were, however, also similar to the  
485 effects found for the PSII inhibitor diuron and its degradation product 3,4-dichloroaniline. So  
486 far, however, there is no evidence that diuron or 3,4-dichloroaniline inhibit AChE in the ZFE  
487 which means that the underlying concept of similarity between those behavioral phenotypes  
488 remains to be elucidated.

489 Behavioral profiles of single compounds being distinct from MoA analogues were observed  
490 for diclofenac, isoproteruron, endosulfan, and fipronil. This might be explained by the  
491 differences in chemical structures compared to anticipated MoA analogues. For example, the  
492 insecticides endosulfan and fipronil are assigned as GABA-gated chloride channel  
493 antagonists but belong to two different chemical classes, namely organochlorines and  
494 phenylpyrazoles, respectively. In addition, endosulfan is thought to specifically act on certain  
495 arachnids whereas fipronil is known as a specific disruptor of the central nervous system in  
496 insects. In our study, endosulfan caused an anti-cyclic light-dark response whereas fipronil  
497 provoked a completely different hypoactive phenotype. There are indications that fipronil  
498 does not (primarily) act as a GABA-R antagonist in ZFEs but rather inhibits glycine receptors  
499 <sup>45</sup>. In contrast, known GABA-R antagonists like pentylentetrazole and picrotoxin were found  
500 to reverse the normal light-dark response in zebrafish larvae <sup>46, 47</sup> as endosulfan did in our  
501 study. Hence, GABA-R antagonists may be identified via this specific phenotype.

502 Finally, our results demonstrate that behavioral alteration alone cannot be seen as a specific  
503 parameter exclusively indicating effects of anticipated neuroactive substances. A refined  
504 investigation of specificity using a larger set of chemicals and including compounds with  
505 distinct known neuroactive MoAs (e.g. certain pharmaceuticals) that serve as a phenotypical  
506 reference may further improve and establish LMR tests as diagnostic tools. In addition, a  
507 sophisticated test design consisting of a more complex application of stimuli as used by Brun  
508 et al. <sup>10</sup> in the context of neuropharmaceutical discovery might be necessary for behavior-  
509 based distinction of chemicals according to their MoAs. Furthermore, besides using the total  
510 distance moved as endpoint, an additional integration of other parameters and endpoints

511 such as time spent moving or direction of movement as demonstrated by Palmér et al. <sup>48</sup> may  
512 refine the resulting patterns and may help to increase specificity.

513 As a measure for sensitivity of locomotor activity-based endpoints we compared ratios of  
514 effect concentrations for acute toxicity and behavioral alteration. Our results demonstrate that  
515 significant behavioral effects mostly occurred throughout a narrow concentration range at the  
516 borderline to lethality, in most cases covering only one order of magnitude or less. This holds  
517 true for some anticipated neuroactive but also for the other compounds. A higher sensitivity  
518 of the LMR assay was identified for the SSR/SNR inhibitors citalopram and venlafaxine with  
519 ratios  $\geq 9.3$  after 22.5 h of exposure as well as for the GABA-R antagonist endosulfan. We  
520 found that the behavioral responses and the acute toxicity converged with increasing  
521 exposure duration except for venlafaxine and isoproturon which did not cause lethality up to  
522 the limit of water solubility. In contrast to previous findings showing an increased sensitivity  
523 through behavioral endpoints using exposure from 2-98 hpf <sup>9</sup>, we could not confirm that this  
524 type of LMR test in general provides a substantial increase in sensitivity beyond the acute  
525 toxicity levels when exposure is initiated at later embryonic stages. Klüver et al. <sup>9</sup> investigated  
526 e.g. the AChE inhibitor aldicarb and found a 660-fold increase in sensitivity compared to  
527 mortality in the 4-day acute FET test when using a light-dark transition test at 98 hpf. By  
528 contrast, we detected a merely 2-fold increase in sensitivity for the AChE inhibitors diazinon  
529 and triphenylphosphate with our short-term exposure regime in older stages. These  
530 differences might, however, be explained by unspecific activities of diazinon and  
531 triphenylphosphate as we detected AChE inhibition at levels close to baseline toxicity  
532 (Supporting Figure S4). For endosulfan an EC50 (LMR assay) of 0.015  $\mu\text{M}$  after 96 h of  
533 exposure was reported by Klüver et al. <sup>9</sup> without mortality up to the limit of water solubility.  
534 Here we determined a similar EC50 of 0.031  $\mu\text{M}$  within a 4 times shorter exposure window  
535 (96-118.5 hpf) but, in contrast to the previous study, we already observed mortality after  
536 22.5 h of exposure and extrapolated an LC50 (96-118.5 hpf) of 1.2  $\mu\text{M}$ . We assume that the  
537 observed hyperactivity due to the interaction of endosulfan with the GABA-R leads to  
538 increased energy consumption and allocation and finally to mortality. Especially at 5 dpf this

539 appears critical because internal energy resources in form of yolk are exhausted <sup>49</sup>. The  
540 limited GABA-R availability before 96 hpf <sup>29</sup>, therefore, may prohibit an acute toxicity of  
541 endosulfan in earlier stages of embryonic development. These findings indicate that toxicity  
542 testing of compounds with molecular targets not expressed in the early embryo might be  
543 supported by additional LMR analyses at 4 dpf or should be performed in later embryonic  
544 stages.

545 **Supporting Information**

546 S1. Materials and Methods

547 Supporting Table S1. Tested concentrations in  $\mu\text{M}$  and their identification number

548 Supporting Table S2. Toxicity data used for comparative analysis of acute fish embryo  
549 toxicity and LMR data

550 Supporting Table S3. Median moved distances per minute for the 18 investigated  
551 compounds

552 Supporting Figure S1. Chemical structures of the tested compounds

553 Supporting Figure S2. Overview on behavioral profiles of the 18 investigated compounds  
554 recorded after 1.5, 6.0 and 22.5 h of exposure

555 Supporting Figure S3. Concentration-response curves for zebrafish embryo locomotor  
556 alteration

557 Supporting Figure S4. Acetylcholinesterase activity in 120 hpf zebrafish embryos after 24 h  
558 of exposure with diazinon and triphenylphosphate, respectively

559 **Acknowledgement**

560 We gratefully acknowledge Janet Krüger for technical support in the lab. Furthermore, we  
561 thank Stefan Lips and Andreas Schüttler for their support in the development of R scripts  
562 necessary for graphical result representation. Stefan Scholz is acknowledged for critical  
563 comments on a previous version of the manuscript and for helping with KNIME workflow  
564 development for data evaluation. We thank the three unknown reviewers for their  
565 constructive suggestions.

566 **Funding**

567 The present study was supported by the German Federal Environmental Foundation  
568 Scholarship Program (AZ: 80016/222) and the European Union 7<sup>th</sup> Framework Program  
569 project SOLUTIONS (grant agreement no. 603437).

## 570 **References**

- 571 1. Busch, W., Schmidt, S., Kuhne, R., Schulze, T., Krauss, M., and Altenburger, R. (2016)  
572 Micropollutants in European rivers: A mode of action survey to support the  
573 development of effect-based tools for water monitoring, *Environ Toxicol Chem* 35,  
574 1887-1899.
- 575 2. Llorens, J., Li, A. A., Ceccatelli, S., and Sunol, C. (2012) Strategies and tools for  
576 preventing neurotoxicity: to test, to predict and how to do it, *Neurotoxicology* 33, 796-  
577 804.
- 578 3. Agid, Y., Buzsaki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J. A., Grace, A.,  
579 Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G.,  
580 Somogyi, P., Spedding, M., Svenningsson, P., and Weinberger, D. (2007) How can  
581 drug discovery for psychiatric disorders be improved?, *Nat Rev Drug Discov* 6, 189-  
582 201.
- 583 4. Altenburger, R., Scholze, M., Busch, W., Escher, B. I., Jakobs, G., Krauss, M., Kruger, J.,  
584 Neale, P. A., Ait-Aissa, S., Almeida, A. C., Seiler, T. B., Brion, F., Hilscherova, K.,  
585 Hollert, H., Novak, J., Schlichting, R., Serra, H., Shao, Y., Tindall, A., Tolefsen, K. E.,  
586 Umbuzeiro, G., Williams, T. D., and Kortenkamp, A. (2018) Mixture effects in samples  
587 of multiple contaminants - An inter-laboratory study with manifold bioassays, *Environ*  
588 *Int* 114, 95-106.
- 589 5. OECD (2013) *Test No. 236: Fish Embryo Acute Toxicity (FET) Test*, OECD Guidelines for  
590 the Testing of Chemicals, Section 2, OECD Publishing, Paris.
- 591 6. OECD (1992) *Test No. 203: Fish, Acute Toxicity Test*, OECD Guidelines for the Testing of  
592 Chemicals, Section 2, OECD Publishing, Paris.

- 593 7. Lammer, E., Carr, G. J., Wendler, K., Rawlings, J. M., Belanger, S. E., and Braunbeck, T.  
594 (2009) Is the fish embryo toxicity test (FET) with the zebrafish (*Danio rerio*) a potential  
595 alternative for the fish acute toxicity test?, *Comp Biochem Physiol C Toxicol*  
596 *Pharmacol* 149, 196-209.
- 597 8. Scholz, S., Klüver, N., and Kühne, R. (2016) Analysis of the relevance and adequateness  
598 of using Fish Embryo Acute Toxicity (FET) Test Guidance (OECD 236) to fulfil the  
599 information requirements and addressing concerns under REACH.
- 600 9. Klüver, N., König, M., Ortmann, J., Massei, R., Paschke, A., Kühne, R., and Scholz, S.  
601 (2015) Fish embryo toxicity test: identification of compounds with weak toxicity and  
602 analysis of behavioral effects to improve prediction of acute toxicity for neurotoxic  
603 compounds, *Environ Sci Technol* 49, 7002-7011.
- 604 10. Bruni, G., Rennekamp, A. J., Velenich, A., McCarroll, M., Gendele, L., Fertsch, E.,  
605 Taylor, J., Lakhani, P., Lensen, D., Evron, T., Lorello, P. J., Huang, X. P., Kolczewski,  
606 S., Carey, G., Caldarone, B. J., Prinssen, E., Roth, B. L., Keiser, M. J., Peterson, R.  
607 T., and Kokel, D. (2016) Zebrafish behavioral profiling identifies multitarget  
608 antipsychotic-like compounds, *Nat Chem Biol* 12, 559-566.
- 609 11. Kokel, D., Bryan, J., Laggner, C., White, R., Cheung, C. Y., Mateus, R., Healey, D., Kim,  
610 S., Werdich, A. A., Haggarty, S. J., Macrae, C. A., Shoichet, B., and Peterson, R. T.  
611 (2010) Rapid behavior-based identification of neuroactive small molecules in the  
612 zebrafish, *Nat Chem Biol* 6, 231-237.
- 613 12. Legradi, J., el Abdellaoui, N., van Pomeroy, M., and Legler, J. (2015) Comparability of  
614 behavioural assays using zebrafish larvae to assess neurotoxicity, *Environ Sci Pollut*  
615 *Res Int* 22, 16277-16289.
- 616 13. Fraser, T. W. K., Khezri, A., Jurdado, J. G. H., Lewandowska-Sabat, A. M., Henry, T.,  
617 and Ropstad, E. (2017) Toxicant induced behavioural aberrations in larval zebrafish  
618 are dependent on minor methodological alterations, *Toxicol Lett* 276, 62-68.

- 619 14. Warnes, G., Bolker, B., Bonebakker, L., Gentleman, R., Huber, W., Liaw, A., Lumley, T.,  
620 Mächler, M., Magnusson, A., and Möller, S. (2005) gplots: Various R programming  
621 tools for plotting data, 2.
- 622 15. Shi, Q., Wang, M., Shi, F., Yang, L., Guo, Y., Feng, C., Liu, J., and Zhou, B. (2018)  
623 Developmental neurotoxicity of triphenyl phosphate in zebrafish larvae, *Aquat Toxicol*  
624 203, 80-87.
- 625 16. McMillan, D. C., Bradshaw, T. P., Hinson, J. A., and Jollow, D. J. (1991) Role of  
626 metabolites in propanil-induced hemolytic anemia, *Toxicol Appl Pharmacol* 110, 70-  
627 78.
- 628 17. Hill, R. L., Jr., and Janz, D. M. (2003) Developmental estrogenic exposure in zebrafish  
629 (*Danio rerio*): I. Effects on sex ratio and breeding success, *Aquat Toxicol* 63, 417-  
630 429.
- 631 18. Le Fol, V., Ait-Aissa, S., Sonavane, M., Porcher, J. M., Balaguer, P., Cravedi, J. P.,  
632 Zalko, D., and Brion, F. (2017) In vitro and in vivo estrogenic activity of BPA, BPF and  
633 BPS in zebrafish-specific assays, *Ecotoxicol Environ Saf* 142, 150-156.
- 634 19. Liesivuori, J., and Savolainen, H. (1991) Methanol and formic acid toxicity: biochemical  
635 mechanisms, *Pharmacol Toxicol* 69, 157-163.
- 636 20. Scholz, S., Schreiber, R., Armitage, J., Mayer, P., Escher, B. I., Lidzba, A., Leonard, M.,  
637 and Altenburger, R. (2018) Meta-analysis of fish early life stage tests-Association of  
638 toxic ratios and acute-to-chronic ratios with modes of action, *Environ Toxicol Chem*  
639 37, 955-969.
- 640 21. Massei, R., Busch, W., Wolschke, H., Schinkel, L., Bitsch, M., Schulze, T., Krauss, M.,  
641 and Brack, W. (2018) Screening of Pesticide and Biocide Patterns As Risk Drivers in  
642 Sediments of Major European River Mouths: Ubiquitous or River Basin-Specific  
643 Contamination?, *Environ Sci Technol* 52, 2251-2260.
- 644 22. Khetan, S. K., and Collins, T. J. (2007) Human pharmaceuticals in the aquatic  
645 environment: a challenge to Green Chemistry, *Chem Rev* 107, 2319-2364.

- 646 23. Crane, M., Watts, C., and Boucard, T. (2006) Chronic aquatic environmental risks from  
647 exposure to human pharmaceuticals, *Sci Total Environ* 367, 23-41.
- 648 24. de Esch, C., van der Linde, H., Slieker, R., Willemsen, R., Wolterbeek, A., Woutersen,  
649 R., and De Groot, D. (2012) Locomotor activity assay in zebrafish larvae: influence of  
650 age, strain and ethanol, *Neurotoxicol Teratol* 34, 425-433.
- 651 25. Winata, C. L., Korzh, S., Kondrychyn, I., Zheng, W., Korzh, V., and Gong, Z. (2009)  
652 Development of zebrafish swimbladder: The requirement of Hedgehog signaling in  
653 specification and organization of the three tissue layers, *Dev Biol* 331, 222-236.
- 654 26. Irons, T. D., Kelly, P. E., Hunter, D. L., Macphail, R. C., and Padilla, S. (2013) Acute  
655 administration of dopaminergic drugs has differential effects on locomotion in larval  
656 zebrafish, *Pharmacol Biochem Behav* 103, 792-813.
- 657 27. Schmidt, R., Strahle, U., and Scholpp, S. (2013) Neurogenesis in zebrafish - from  
658 embryo to adult, *Neural Dev* 8, 3.
- 659 28. Cocco, A., Ronnberg, A. M., Jin, Z., Andre, G. I., Vossen, L. E., Bhandage, A. K.,  
660 Thornqvist, P. O., Birnir, B., and Winberg, S. (2017) Characterization of the gamma-  
661 aminobutyric acid signaling system in the zebrafish (*Danio rerio* Hamilton) central  
662 nervous system by reverse transcription-quantitative polymerase chain reaction,  
663 *Neuroscience* 343, 300-321.
- 664 29. Monesson-Olson, B., McClain, J. J., Case, A. E., Dorman, H. E., Turkewitz, D. R.,  
665 Steiner, A. B., and Downes, G. B. (2018) Expression of the eight GABAA receptor  
666 alpha subunits in the developing zebrafish central nervous system, *PLoS One* 13,  
667 e0196083.
- 668 30. Küster, E. (2005) Cholin- and carboxylesterase activities in developing zebrafish embryos  
669 (*Danio rerio*) and their potential use for insecticide hazard assessment, *Aquat Toxicol*  
670 75, 76-85.
- 671 31. Teixido, E., Pique, E., Gomez-Catalan, J., and Llobet, J. M. (2013) Assessment of  
672 developmental delay in the zebrafish embryo teratogenicity assay, *Toxicol In Vitro* 27,  
673 469-478.

- 674 32. Soreq, H., and Seidman, S. (2001) Acetylcholinesterase--new roles for an old actor, *Nat*  
675 *Rev Neurosci* 2, 294-302.
- 676 33. Behra, M., Cousin, X., Bertrand, C., Vonesch, J. L., Biellmann, D., Chatonnet, A., and  
677 Strahle, U. (2002) Acetylcholinesterase is required for neuronal and muscular  
678 development in the zebrafish embryo, *Nat Neurosci* 5, 111-118.
- 679 34. Yang, D., Lauridsen, H., Buels, K., Chi, L. H., La Du, J., Bruun, D. A., Olson, J. R.,  
680 Tanguay, R. L., and Lein, P. J. (2011) Chlorpyrifos-oxon disrupts zebrafish axonal  
681 growth and motor behavior, *Toxicol Sci* 121, 146-159.
- 682 35. Thompson, W. A., Arnold, V. I., and Vijayan, M. M. (2017) Venlafaxine in Embryos  
683 Stimulates Neurogenesis and Disrupts Larval Behavior in Zebrafish, *Environ Sci*  
684 *Technol* 51, 12889-12897.
- 685 36. Velki, M., Di Paolo, C., Nelles, J., Seiler, T. B., and Hollert, H. (2017) Diuron and diazinon  
686 alter the behavior of zebrafish embryos and larvae in the absence of acute toxicity,  
687 *Chemosphere* 180, 65-76.
- 688 37. Liu, Z., Wang, Y., Zhu, Z., Yang, E., Feng, X., Fu, Z., and Jin, Y. (2016) Atrazine and its  
689 main metabolites alter the locomotor activity of larval zebrafish (*Danio rerio*),  
690 *Chemosphere* 148, 163-170.
- 691 38. Xia, L., Zheng, L., and Zhou, J. L. (2017) Effects of ibuprofen, diclofenac and  
692 paracetamol on hatch and motor behavior in developing zebrafish (*Danio rerio*),  
693 *Chemosphere* 182, 416-425.
- 694 39. Jin, Y., Zhu, Z., Wang, Y., Yang, E., Feng, X., and Fu, Z. (2016) The fungicide imazalil  
695 induces developmental abnormalities and alters locomotor activity during early  
696 developmental stages in zebrafish, *Chemosphere* 153, 455-461.
- 697 40. Bretaud, S., Toutant, J. P., and Saglio, P. (2000) Effects of carbofuran, diuron, and  
698 nicosulfuron on acetylcholinesterase activity in goldfish (*Carassius auratus*),  
699 *Ecotoxicol Environ Saf* 47, 117-124.

- 700 41. Velki, M., Meyer-Alert, H., Seiler, T. B., and Hollert, H. (2017) Enzymatic activity and  
701 gene expression changes in zebrafish embryos and larvae exposed to pesticides  
702 diazinon and diuron, *Aquat Toxicol* 193, 187-200.
- 703 42. Brox, S., Seiwert, B., Kuster, E., and Reemtsma, T. (2016) Toxicokinetics of Polar  
704 Chemicals in Zebrafish Embryo (*Danio rerio*): Influence of Physicochemical  
705 Properties and of Biological Processes, *Environ Sci Technol* 50, 10264-10272.
- 706 43. Ali, S., Champagne, D. L., and Richardson, M. K. (2012) Behavioral profiling of zebrafish  
707 embryos exposed to a panel of 60 water-soluble compounds, *Behav Brain Res* 228,  
708 272-283.
- 709 44. Liu, X., Jung, D., Jo, A., Ji, K., Moon, H. B., and Choi, K. (2016) Long-term exposure to  
710 triphenylphosphate alters hormone balance and HPG, HPI, and HPT gene expression  
711 in zebrafish (*Danio rerio*), *Environ Toxicol Chem* 35, 2288-2296.
- 712 45. Stehr, C. M., Linbo, T. L., Incardona, J. P., and Scholz, N. L. (2006) The developmental  
713 neurotoxicity of fipronil: notochord degeneration and locomotor defects in zebrafish  
714 embryos and larvae, *Toxicol Sci* 92, 270-278.
- 715 46. Ellis, L. D., Seibert, J., and Soanes, K. H. (2012) Distinct models of induced hyperactivity  
716 in zebrafish larvae, *Brain Res* 1449, 46-59.
- 717 47. Yang, X., Lin, J., Peng, X., Zhang, Q., Zhang, Y., Guo, N., Zhou, S., and Li, Q. (2017)  
718 Effects of picrotoxin on zebrafish larvae behaviors: A comparison study with PTZ,  
719 *Epilepsy Behav* 70, 224-231.
- 720 48. Palmér, T., Ek, F., Enqvist, O., Olsson, R., Astrom, K., and Petersson, P. (2017) Action  
721 sequencing in the spontaneous swimming behavior of zebrafish larvae - implications  
722 for drug development, *Sci Rep* 7, 3191.
- 723 49. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., and Schilling, T. F. (1995)  
724 Stages of embryonic development of the zebrafish, *Dev Dyn* 203, 253-310.

725

1 **Supporting Information**

2 **Authors:**

3 David Leuthold<sup>1\*</sup>, Nils Klüver<sup>2</sup>, Rolf Altenburger<sup>1</sup>, Wibke Busch<sup>1</sup>

4 <sup>1</sup>Helmholtz-Centre for Environmental Research – UFZ, Dept. Bioanalytical Ecotoxicology,  
5 Permoser Str. 15, 04318 Leipzig, Germany

6 <sup>2</sup>Helmholtz-Centre for Environmental Research – UFZ, Dept. Cell Toxicology, Permoser Str.  
7 15, 04318 Leipzig, Germany

8 \*corresponding author: david.leuthold@ufz.de

9 **Title:**

10 Can environmentally relevant neuroactive chemicals specifically be detected with the  
11 locomotor response test in zebrafish embryos?

12 **Number of pages:**

13 14

14 **Figures:**

15 Supporting Figure S1, Supporting Figure S2, Supporting Figure S3, Supporting Figure S4

16 **Tables:**

17 Supporting Table S1, Supporting Table S2, Supporting Table S3 (EXCEL file)

18 **S1. Materials and Methods**

19 **Fish cultivation and embryo collection.** Adult zebrafish (*D. rerio*) of the strain UFZ-OBI  
20 (generation F14) were kept in 120-L aquaria (activated carbon-filtered tap water, 26.5±1 °C)  
21 with a photoperiod of 14:10 h light:dark. Commercial dry food and *Artemia* sp. were fed once  
22 and twice a day, respectively. Fish were cultured and used according to German and  
23 European animal protection standards and fish culture was approved by the Government of  
24 Saxony (Landesdirektion Leipzig, file number 75–9185.64). Zebrafish eggs were collected  
25 within stainless steel sieve-covered glass dishes. Fertilized eggs were selected by means of  
26 microscopy and were subsequently transferred into oxygen-aerated (≥ 24 h) and pH-adjusted  
27 (pH 7.4±0.1) standard dilution water as specified in ISO 7346-3 (80 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, 20 mM  
28 MgSO<sub>4</sub>·7H<sub>2</sub>O, 31 mM NaHCO<sub>3</sub>, 3.1 mM KCl) with a density of 1 egg per 2 mL. Afterwards,  
29 zebrafish embryos were incubated at 28 °C with a 14:10 h light:dark cycle until initiation of  
30 exposure at 96 hpf (hours post fertilization).

31 **Chemicals and stock preparation.** Chemical stocks were either prepared directly in  
32 standard dilution water with a final concentration of 0.1% v/v methanol the day prior to testing  
33 or chemicals were dissolved in pure methanol (≥99.8%, CAS RN 67-56-1, J.T. Baker®,  
34 Avantor Performance Materials Inc, Pennsylvania, USA). Test solutions were then produced  
35 from serial dilution of stock solutions shortly before exposure. The final concentration of  
36 methanol was 0.1% v/v in every exposure solution. pH and oxygen levels of exposure  
37 (highest concentration tested per plate) and control media at initiation of exposure were  
38 7.6±0.1 and 91.1±3.5%, and 7.5±0.1 and 92.6±3.5% (mean±standard deviation),  
39 respectively. Chemicals and purities purchased from Sigma-Aldrich (Steinheim, Germany)  
40 were (-)-nicotine (98.7%, CAS RN 54-11-5), 3,4-dichloroaniline (99.9%, CAS RN 95-76-1),  
41 bisphenol A (≥99.0%, CAS RN 80-05-7), cyprodinil (99.9%, CAS RN 121552-61-2),  
42 diclofenac sodium (≥98.0%, CAS RN 15307-79-6), endosulfan (99.4%, CAS RN 115-29-7),  
43 fipronil (97.9%, CAS RN 120068-37-3), naproxen sodium (98.0-102.0%, CAS RN 26159-34-  
44 2) and triphenylphosphate (≥99.0%, CAS RN 115-86-6). Chemicals and purities purchased

45 from Sigma-Aldrich (Buchs, Switzerland) were diazinon (98.5%, CAS RN 333-41-5), diuron  
46 ( $\geq 98.0\%$ , CAS RN 330-54-1), imidacloprid ( $\geq 98.0\%$ , CAS RN 138261-41-3), isoproturon  
47 (99.8%, CAS RN 34123-59-6) and pyrimethanil (99.9%, CAS RN 53112-28-0). Furthermore,  
48 4-n-nonylphenol (99.9%, CAS RN 104-40-5, Riedel de Haën, Honeywell Specialty  
49 Chemicals, Seelze, Germany), citalopram hydrobromide (95.0%, CAS RN 59729-32-7,  
50 Fluorochem Ltd Hadfield, UK), and D,L-venlafaxine (98.0%, CAS RN 93413-69-5, Santa  
51 Cruz Biotechnology Inc Dallas, Texas, USA) were used as model compounds.

52 **Exposure.** Immediately after exposure was initiated, individuals were transferred separately  
53 to single square-shaped flat bottom wells of a 96-well clear polystyrene plate (Whatman™  
54 microplate devices, uniplate®, GE Healthcare UK Limited, Buckinghamshire, UK). The  
55 volume of test solution within each well was 400  $\mu\text{L}$ . Subsequently, plates were covered with  
56 cell culture test plate lids (Techno Plastic Products, Trasadingen, Switzerland) and sealed  
57 with laboratory film (Pechiney Plastic Packaging, Chicago, Illinois, USA). In case of volatile  
58 compounds (3,4-dichloroaniline, diazinon, endosulfan, methanol, nicotine), plates were  
59 additionally sealed with a self-adhesive polyester film originally intended for real time PCR  
60 (Th. Geyer, Wertheim, Germany).

61 **Light-dark transition locomotor response test.** An incubator surrounding the ZebraBox  
62 was used to maintain a constant temperature of 28 °C ( $27.4 \pm 0.9$  °C; mean  $\pm$  standard  
63 deviation). Tracking was initiated right after placing the plate within the measuring chamber.  
64 Light intensities during dark and light photoperiods were 0 and 172  $\mu\text{mol/s/m}^2$  per  $\mu\text{A}$ ,  
65 respectively. Tracking was conducted with continuous infrared illumination and recorded via  
66 an infrared camera. Videos were recorded at a rate of 25 images per second and data was  
67 binned into 1-min intervals. The detection threshold was set to 0.2 mm/s defining larvae as  
68 being inactive below this level. Besides mortality, apparent morphological abnormalities were  
69 recorded subsequent to each LMR test. Observed malformations included brain necrosis,  
70 axis distortion, edema formation and fin deformation. However, morphological alterations  
71 showed up at concentrations subsequently causing mortality within the observation interval

72 ( $\leq 120$  hpf). The influence of time of day on the outcome of the LMR assay was excluded by  
73 measuring at the same time, i.e. at ~08:00 AM, 02:00 PM, and 06:00 AM, respectively.

74 **Analysis of locomotor activity data.** In order to identify significant differences between  
75 control (C) and treatment (T), a 95% confidence interval (CI) per minute for both was  
76 calculated using

$$CI_{2.5} = \frac{n}{2} - \frac{1.96\sqrt{n}}{2} \quad \text{Equation 1}$$

77 as lower limit and

$$CI_{97.5} = 1 + \frac{n}{2} + \frac{1.96\sqrt{n}}{2} \quad \text{Equation 2}$$

78 as upper limit, with  $n$  being the number of embryos tested per concentration and 1.96 being  
79 the approximate value of the 97.5% percentile. For the calculation of CI(C) all controls per  
80 tested compound were included. More specifically, T was considered hypoactive if the lower  
81 control limit ( $CI_{2.5}(C)$ ) was above the upper treatment limit ( $CI_{97.5}(T)$ ) and hyperactive if the  
82 upper control limit ( $CI_{97.5}(C)$ ) was below the lower treatment limit ( $CI_{2.5}(T)$ ), respectively.

83 Finally, absolute distances in mm between the CIs of C and T for each minute were summed  
84 up per test concentration as a measure of the total effect. Subsequently, a concentration  
85 response curve was fitted to the total effect and, as a measure of sensitivity, an EC50 was  
86 calculated for each compound (Equation 3). Because multiphasic concentration response  
87 patterns were observed for many of the examined compounds, modelling merely  
88 incorporated data up to the maximum observed total effect but not beyond to account for  
89 MoA-unrelated secondary effects. Additionally, to determine the relative contribution of hypo-  
90 and hyperactive behavior to the total effect, the respective distances between CIs considered  
91 for concentration response modelling were summed up. This approach was performed for  
92 every compound and every measurement time point separately. Statistically significant  
93 differences between the measurement time points were not addressed here.

94 **Concentration-response modelling.** Concentration-response modelling of behavioral effect  
95 and lethality data was performed using a 4-parameter logistic function

$$y = E_0 + \frac{E_{max} * x^h}{EC_{50}^h + x^h} \quad \text{Equation 3}$$

96 with y being the modeled effect,  $E_0$  and  $E_{max}$  are the minimum and maximum effect set at 0  
97 and the corresponding maximum observed effect per compound, respectively. I.e. 0 to 100%  
98 lethality and 0 to the maximum difference in distance moved between treatment and control  
99 in mm, respectively. x refers to exposure concentration,  $EC_{50}$  is the concentration causing a  
100 half maximum effect, and h (Hill factor) represents the slope of the tangent in the inflection  
101 point of the model.

102 **Multidimensional scaling.** A distance matrix was calculated (KNIME Distance Matrix  
103 Calculate node) using the median distance moved per minute for each treatment and control  
104 group. Euclidean distances were used for ordination in two-dimensional space in which the  
105 relative distance between single samples reflects their similarity in terms of behavior. Hence,  
106 samples located close to each other show a high degree of similarity.

107 **Cluster analysis.** Due to the circumstance that overall 179 concentrations were tested and  
108 in order to visualize clusters more clearly, a maximum of four test concentrations per  
109 compound was included in cluster analysis. Therefore, three categories were formed based  
110 on the modeled mortality after 22.5 h of exposure (96-118.5 hpf): category 1: mortality < 5%,  
111 category 2:  $5\% \leq \text{mortality} \leq 50\%$ , and category 3:  $50\% < \text{mortality} < 100\%$ . Since one dead  
112 individual out of 16 used per treatment yields 6% mortality, category 1 describes behavioral  
113 effects in the absence of mortality. For each category the concentrations causing the most  
114 pronounced and significant (see 'Analysis of locomotor activity data' in this section (S1))  
115 effect across all three time points (1.5, 6.0, 22.5 h of exposure) were chosen for cluster  
116 analysis (largest sum of distances spent in hypo- and hyperactivity, respectively, for category  
117 1; largest overall sum of distances spent in hypo- and hyperactivity for category 2 and 3,  
118 respectively). Consequently, each of the time points of the investigation are comparable

119 since the selection of test concentrations for each of them is the same. For the selected  
120 concentrations the differences between the median distance moved per minute of treatment  
121 and control were calculated and used for hierarchical clustering. The applied distance and  
122 cluster functions were 'euclidean' and 'complete', respectively.

123 **Supporting Table S1.** Tested concentrations in  $\mu\text{M}$  and their identification number.

Concentration no.	Diazinon	Triphenylphosphate	Citalopram	Ventaxine	Nicotine	Imidacloprid	Endosulfan	Fipronil	Methanol	Diclofenac	Naproxen	Isoproterenol	Diuron	3,4-Dichloroaniline	Nonylphenol	Bisphenol A	Cyprodinil	Pyrimethanil
c1	2.7	0.9	0.1	0.007	10.1	9.3	0.003	0.2	33738.8	0.6	105.6	82.6	0.9	8.5	0.7	6.3	0.8	53.8
c2	3.6	1.3	0.2	0.014	15.1	18.6	0.006	0.4	67477.7	1.2	143.6	104.9	2.3	13.9	1.5	9.0	1.2	68.8
c3	5.4	1.8	0.3	0.028	20.2	37.3	0.012	0.5	89979.3	2.6	195.3	133.2	5.6	22.8	3.6	12.9	2.0	88.1
c4	7.2	2.7	0.7	0.055	30.3	74.6	0.025	0.7	134955.4	5.5	265.7	169.2	13.8	37.4	8.2	18.5	3.1	112.8
c5	10.8	3.6	1.3	0.110	40.4	149.1	0.049	1.1	179949.5	11.7	361.3	214.9	33.9	61.3	11.1	26.4	5.0	144.4
c6	14.4	5.4	2.7	0.220	60.6	298.2	0.098	1.4	269910.8	25.0	491.4	271.9	82.9	100.6	14.5	37.8	8.0	184.8
c7	21.6	7.2	5.4	0.440	80.8	596.5	0.197	2.2	359881.0	53.2	668.2	340.3	152.7	165.0	19.0	54.0	12.8	236.5
c8	28.9	10.8	10.8	0.881	121.1	1193.0	0.393	2.9	539821.5	113.4	908.8	-	-	270.5	25.0	77.2	20.5	302.7
c9	43.3	14.4	21.6	1.761	161.5	2385.0	0.786	4.3	719762.3	241.5	1236.0	-	-	443.7	28.8	110.4	32.8	387.5
c10	57.7	21.6	43.1	3.522	242.2	-	-	8.6	1079643.0	-	-	-	-	-	-	-	-	-
c11	86.6	-	86.2	7.044	-	-	-	-	1439524.0	-	-	-	-	-	-	-	-	-
c12	115.4	-	172.5	14.089	-	-	-	-	2879048.1	-	-	-	-	-	-	-	-	-
c13	-	-	345.0	28.178	-	-	-	-	-	-	-	-	-	-	-	-	-	-
c14	-	-	-	56.356	-	-	-	-	-	-	-	-	-	-	-	-	-	-
c15	-	-	-	112.712	-	-	-	-	-	-	-	-	-	-	-	-	-	-
c16	-	-	-	225.424	-	-	-	-	-	-	-	-	-	-	-	-	-	-
c17	-	-	-	450.848	-	-	-	-	-	-	-	-	-	-	-	-	-	-

124

125 Each compound was tested down to a concentration where no obvious difference to the control movement pattern was visible anymore (manual

126 inspection of raw data plots), and up to a level where ideally, at least at the last time point of assessment (118.5 hpf),  $\leq 100\%$  mortality were

127 observed in order to allow for concentration-response modelling. Therefore, the R package drc (version 2.3-96, <sup>1</sup>) implemented in KNIME Analytics  
128 Platform (version 3.2.1, August 19, 2016, KNIME GmbH, Konstanz, Germany) was used, applying a 4-parameter logistic function (Equation 3).


129 **Supporting Table S2.** Toxicity data used for comparative analysis of acute fish embryo toxicity and LMR data.

Compound	LC50 (µmol/L)					EC50 (µmol/L)			Ratio LC50/EC50
	0-96 hpf	0-120 hpf	96-97.5 hpf	96-102 hpf	96-118.5 hpf	96-97.5 hpf	96-102 hpf	96-118.5 hpf	96-118.5 hpf
Diazinon	21.7	18.2	188.5	110.4	80.8	31.2	28.8	39.7	2.0
Triphenylphosphate	5.6	5.7	no effect	531.3	15.4	6.4	6.7	11.2	1.4
Citalopram	674.4	476.8	no effect	no effect	215.0	85.4	182.6	16.9	12.7
Venlafaxine	961.4 <sup>a</sup>	>Sw	no effect	no effect	no effect	1.8	2.6	103.5	9.3
Nicotine	3624.4	4143.9	no effect	372.5	330.6	121.3	100.1	70.3	3.5
Imidacloprid	2386.0 <sup>a</sup>	>Sw	no effect	no effect	4360.6	355.7	1379.9	1262.6	4.7
Endosulfan	0.79 <sup>a</sup>	>Sw	no effect	no effect	1.2	0.24	0.03	0.03	40.0
Fipronil	8.6 <sup>a</sup>	>Sw	no effect	no effect	5.6	2.2	1.2	0.9	6.2
Methanol	0.6×10 <sup>6</sup>	0.6×10 <sup>6</sup>	2.0×10 <sup>6</sup>	1.8×10 <sup>6</sup>	1.5×10 <sup>6</sup>	0.6×10 <sup>6</sup>	0.9×10 <sup>6</sup>	1.0×10 <sup>6</sup>	1.5
Diclofenac*	8.4	7.4	165.5	77.4	77.4	0.7	36.5	no effect	-
Naproxen	344.4	301.4	no effect	1398.3	832.0	675.9	474.1	576.6	1.4
3,4-Dichloroaniline	9.6	18.5	454.5	399.3	333.5	81.1	76.2	105.2	3.2
Diuron	12.9	11.0	no effect	no effect	194.4	16.0	29.5	28.1	6.9
Isoproturon	23.4	35.2	no effect	no effect	no effect	104.2	281.8	198.0	-
Nonylphenol	4.1	3.5	19.2	17.7	12.4	14.3	12.5	10.2	1.2
Bisphenol A	52.0	45.5	no effect	no effect	117.3	29.0	29.5	38.7	3.0
Cyprodinil	2.9	2.5	no effect	no effect	20.8	10.7	22.0	14.1	1.5
Pyrimethanil	18.9	19.0	no effect	no effect	212.8	182.7	211.9	127.6	1.7


130

131 Sw = Limit of water solubility, a = Maximum water solubility used because no mortality was observed. \*Effect concentrations for diclofenac were


132 reduced by 10% in Figure 6 of the main article to avoid overlap of data points.




Diazinon




Triphenylphosphate




Diclofenac




Naproxen




Citalopram




Venlafaxine




Isoproturon




Diuron




3,4-Dichloroaniline




Nicotine




Imidacloprid




Nonylphenol




Bisphenol A




Endosulfan



Fipronil



Cyprodinil




Pyrimethanil

133


134 **Supporting Figure S1.** Chemical structures of the tested compounds.



136 **Supporting Figure S2.** Overview on behavioral profiles of the 18 investigated compounds  
137 recorded after 1.5, 6.0 and 22.5 h of exposure. Profiles were calculated from the difference in  
138 median distance moved per minute of treatment and control. Increasing concentrations are  
139 indicated by grey triangles on the right hand side. Compounds with an anticipated same  
140 mode of action are indicated by uniform color.



142 **Supporting Figure S3.** Concentration-response curves for zebrafish embryo locomotor  
143 alteration after 1.5, 6.0 and 22.5 h of exposure (96-118.5 hpf). Blue and red data points  
144 represent significant differences in the distance moved per minute between treatment and  
145 control, respectively. The maximum observed total effect (sum of distances spent hypo- and  
146 hyperactive) was used as the maximum of each model. Broken vertical lines represent LC05  
147 and LC50, respectively, after 22.5 h of treatment.



148

149 **Supporting Figure S4.** Acetylcholinesterase (AChE) activity in 120 hpf zebrafish embryos  
150 (ZFEs) after 24 h of exposure with (A) diazinon and (B) triphenylphosphate, respectively.  
151 AChE activity was determined photometrically and was normalized to the total protein  
152 content of each sample ( $n=4$  with  $\leq 8$  ZFEs) as previously described <sup>2</sup>. Enzyme activity in  
153 controls was  $34.4 \pm 3.5$  and  $32.5 \pm 1.8$  mOD/min/mg (mean  $\pm$  SD) for diazinon and  
154 triphenylphosphate, respectively.

## 155 References

- 156 1. Ritz, C., and Streibig, J. C. (2005) Bioassay Analysis Using R, 2005 12, 22.
- 157 2. Küster, E. (2005) Cholin- and carboxylesterase activities in developing zebrafish embryos  
158 (Danio rerio) and their potential use for insecticide hazard assessment, *Aquat Toxicol*  
159 75, 76-85.